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The eye is at the forefront of the application of gene therapy techniques to medicine. In the United States, a gene therapy treatment
for Leber’s congenital amaurosis, a rare inherited retinal disease, recently became the ﬁrst gene therapy to be approved by the FDA
for the treatment of disease caused by mutations in a speciﬁc gene. Phase III clinical trials of gene therapy for other single-gene
defect diseases of the retina and optic nerve are also currently underway. However, for optic nerve diseases not caused by
single-gene defects, gene therapy strategies are likely to focus on slowing or preventing neuronal death through the expression
of neuroprotective agents. In addition to these strategies, there has also been recent interest in the potential use of precise
genome editing techniques to treat ocular disease. This review focuses on recent developments in gene therapy techniques for
the treatment of glaucoma and Leber’s hereditary optic neuropathy (LHON). We discuss recent successes in clinical trials for
the treatment of LHON using gene supplementation therapy, promising neuroprotective strategies that have been employed in
animal models of glaucoma and the potential use of genome editing techniques in treating optic nerve disease.
1. Introduction
In the last two decades, human gene therapy has advanced
signiﬁcantly. As our understanding of optic nerve disease
pathologies has improved, the eye has become a particularly
appealing clinical target for gene therapy and genome editing
studies. The eye as a model organ for testing gene therapies
has always been attractive. Firstly, the eye is largely immune
privileged [1, 2] and vectors delivered to the eye are relatively
isolated from the rest of the body. The size and ease of access
to the eye is also favourable allowing small volumes of drug
to be precisely delivered. Furthermore, testing the eﬀective-
ness of treatments via both electrophysiological and psy-
chophysical testing is well-established, quick, and reliable
[3]. Both Leber’s hereditary optic neuropathy (LHON)
and glaucoma are diseases resulting in permanent, irrevers-
ible loss of vision. With an undeniable need to treat and
manage these diseases with novel therapeutic approaches,
gene therapy may hold signiﬁcant beneﬁts in the coming
years [4].
A prerequisite for a successful gene therapy in the eye is a
vector system that leads to long, sustained levels of therapeu-
tic gene expression within a select target cell with minimal
side eﬀects [5, 6]. This is particularly important for chronic,
long-term pathologies such as glaucoma. Of the various non-
viral and viral vector systems that have been used for retinal
gene therapy (i.e., adenovirus, lentivirus, and nanoparticles),
recombinant adeno-associated viral vectors (AAVs) have
proven the most promising. Hundreds of clinical trials have
been performed using AAV vectors spanning back 25 years
[7] with 25 trials currently registered to test AAVs in retinal
diseases (http://clinicaltrials.gov).
AAVs are composed of a 4.7 kb single-stranded genome
packaged within a nonenveloped icosahedral capsid. After
removal of 4.4 kb of the viral genome, vectors can be
packaged with a similar-sized foreign piece of DNA that
can be adjusted and optimized to improve cell-speciﬁc target-
ing and transgene expression via a series of cassette elements
[8]. Various AAV serotypes exist whereby the vector capsid
determines tissue speciﬁcity, with AAV2 regarded as the
most eﬃcient serotype for RGC transduction [9, 10]. In par-
ticular, vectors possessing an AAV2 backbone, cross packed
into capsids from another serotype such as AAV2/2 and
AAV2/6, have been shown to have the highest transduction
eﬃciency in the retina [9]. AAV2/2 has been shown to trans-
duce RGC more than any other cell type, while AAV2/6
displays the most diverse tropism proﬁle, transducing Müller
glia and many neuronal cell types [9].
Promoter choice is also important for cell-speciﬁc
expression and the strength of transgene expression within
the targeted cell. While several RGC-speciﬁc promoters exist
(Table 1), many vectors designed for optic neuropathies
employ a ubiquitous CMV [10–14] or a hybrid CMV early
enhancer/chicken b-actin promoter (CAG) [15–17] due to
their small size and high levels of transgene expression
[18, 19]. Promoter size is particularly important when look-
ing to incorporate larger genes into an AAV. For optic
neuropathies in particular, there is a reduced necessity for a
selective promoter due to the method of delivery into the
eye, which is a compartmentalized structure. The largely cell
void vitreous means that the ﬁrst cells which the vector
particles come into contact with are of the inner retina,
leading to a signiﬁcant transduction of RGCs in the presence
of an appropriate promoter. CMV and CAG promoters have
been shown to facilitate transduction of around 85% of RGCs
in the adult rat eye [10, 16] with similar expression seen in
mice (Figure 1).
Numerous studies support this observation, with both
CMV and CAG promoters increasing expression primarily
in RGCs, although some amacrine, Müller glial, and bipolar
cells are also transduced [10, 14, 25] (Figure 2). Interestingly,
a diﬀerent proﬁle of transduction is observed when the
AAV2-CMV vector is injected at birth as opposed to adult-
hood. When intravitreally injected at P0, transduction is
predominantly observed on rat photoreceptors (50%) com-
pared to largely RGCs (60–70%) if injected in adults [10].
Depending on the gene therapy product and expected
level of expression, careful consideration needs to be taken
to ensure that oﬀ-target transduction does not have adverse
eﬀects on retinal function and health.
There is some limitation to AAV therapies, in particular
the relatively small cargo capacity of AAV vectors for foreign
DNA. Therefore, large genes are not suitable for use in a
standard AAV vector, although dual vector [26] and more
recently triple vector [27] approaches are being designed to
overcome the coding capacity. Splitting large genes into two
Table 1: Promoters typically chosen for transduction of retinal ganglion cells (RGCs) within the eye.
Promoter Speciﬁcity for RGCs Strength of expression in RGCs Oﬀ-target labelling
Size (bp)
% of AAV cargo
References
CMV + +++
Muller glia
Amacrine cells
Bipolar cells
(508–800)
(10–17%)
[10–14]
CAG + ++++
Muller glia
Amacrine cells
Bipolar cells
(584–1132)
(12–24%)
[15–17]
SYN1 +++ ++ Amacrine cells
(400–469)
(8–10%)
[20, 21]
Nefh ++++ +++
(2251)
(48%)
[22]
Thy1 ++++ ++
(6500)
(exceeds limit)
[23]
Mcp-1 ++ +++ injured cells
560 (mouse only)
(12%)
[24]
Figure 1: GFP expression throughout the mouse retina three weeks after intravitreal injection of AAV2-CAG GFP. Image courtesy of Dr.
Andrew Osborne and Dr. Tasneem Khatib.
2 Neural Plasticity
halves and packing them into two independent AAV vectors
has made it possible to treat mouse models of Stargardt’s
disease and Usher syndrome type IB whereby the full-length,
large gene is reconstituted in photoreceptors or the retinal
pigment epithelium via splicing or homologous recombi-
nation [26]. Admittedly, this method is less eﬀective than
single AAV-mediated gene delivery and at present has
not been used to address any genetic defects for glaucoma
or LHON, but it removes a signiﬁcant hurdle in the possible
advancement of larger gene therapies.
For inherited optic nerve diseases where a speciﬁc genetic
defect has been well deﬁned, gene supplementation therapies
have gained considerable ground. Recently, the U.S. FDA
approved the ﬁrst gene therapy for vision loss, created by
Spark Therapeutics Inc., who utilized this approach in clini-
cal trials for Leber’s congenital amaurosis (LCA), a disease
characterized by severe childhood visual loss. In their studies
carried out by Bennett et al. [28], AAV-meditated gene
supplementation was used to compensate for a deﬁciency in
retinal pigment epithelium, caused by a mutation in the
RPE65 gene. One year following phase 3 trials, the mean
bilateral multiluminance mobility test (MLMT) change score
was 1.8 (SD 1.1) light levels in the intervention group and
only 0.2 (1.0) in the control group [29]. The results of this
trial mark a signiﬁcant improvement in functional vision
in patients with RPE65 mutations, a condition that was
previously medically untreatable.
While still unproven, rapid advances in precise genome
editing technologies have provided the possibility of new
gene therapy approaches to optic nerve diseases that have a
clear genetic basis. RNA-guided nucleases (i.e., CRISPR/
Cas9) and designer endonucleases (i.e., TALENs or ZFNs)
[30] have been of particular interest and over the coming
decade are likely to replace many of the current gene
supplementation methods.
While still early in its development, CRISPR/Cas9-
based therapies have already been demonstrated for the
treatment of optic diseases [31, 32]. With this technique,
the CRISPR-associated protein Cas9 creates site-speciﬁc
double-stranded breaks in DNA [33], which can stimulate
host DNA repair mechanisms [34]. In its most widely
used form, this system requires that two components are
expressed in cells: the Cas9 nuclease and a guide RNA
(gRNA), consisting of a fusion of a crRNA and a ﬁxed
tracrRNA. The ﬁrst 20 nucleotides of the gRNA correspond
to the DNA sequence targeted for editing and direct Cas9
to this site using standard RNA–DNA complementarity
base-pairing [35]. Gene knockouts can be created through
nonhomologous end joining (NHEJ), which creates small
nucleotide insertions or deletions (indels) resulting in a
frameshift mutation and termination [36, 37]. Alternatively,
site-speciﬁc integration of transgenes is typically achieved
by homology-directed repair (HDR) in the presence of a
donor DNA template [31]. While this pathway is not avail-
able to nondividing cells, a homology-independent targeted
integration (HITI) strategy has recently been developed
which achieves robust DNA knock-in in both dividing and
nondividing cells in vitro and in vivo [38].
CRISPR/Cas9 can be eﬃciently delivered to select cell
populations in the eye using a dual AAV system. In a
proof-of-concept study by Hung et al. [39], a dual AAV2
system was used to introduce CRISPR/Cas9 into mouse
RGCs in vivo and achieve knockout of a YFP transgene. With
this dual-vector system, one AAV2 delivered SpCas9, while
the other contained a single guide RNA (sgRNA) against
YFP, achieving a knockout rate of 84% in YFP-sgRNA-
infected retinal cells. Similarly, Yu et al. [31]. delivered
CRISPR/Cas9 using a dual AAV system to therapeutically
target the Nrl gene in postmitotic photoreceptors in mice.
Deep sequencing of the targeted region indicated that 98%
of total reads included changes almost exclusively at the
targeted genome site.
Before CRISPR/Cas9 approaches can be transitioned
to clinical use, the frequency of oﬀ-target activity and
modiﬁcation remains a major concern that will need to
be assessed [35]. Possible long-term consequences may
include Cas9 activation or repression, and possible epige-
netic editing, although while long-term AAV-mediated gene
expression is beneﬁcial for gene supplementation therapies,
CRISPR/Cas9 only requires a short period of expression
[40]. Studies by Chew et al. [41] found that the editing
frequency of CRISPR/Cas9 and its oﬀ-target eﬀects had
dose dependency. It is therefore likely that continuous
AAV expression could contribute to a rise in oﬀ-target
modiﬁcation and should be considered when assessing
these therapies.
Figure 2: GFP expression and colocalization with retinal markers three weeks after intravitreal injection of AAV2-CAG GFP into the mouse
eye. TUJ1 = retinal ganglion cells; CALBINDIN= amacrine cells. Image courtesy of Dr. Andrew Osborne.
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Conditions with an unclear or heterogeneous etiology,
however, will still require a gene therapy such as AAV that
focuses on enhancing survival of neurons by manipulating
molecular pathways in the host cell rather than by correcting
a primary genetic defect. The rest of this review will focus on
current strategies for the optic neuropathies glaucoma and
LHON with a focus on AAV-mediated protection and the
possibility of genome editing as a potential future treatment.
2. Gene Therapy to Treat
Adult-Onset Glaucoma
Glaucoma is a group of eye diseases characterized by pro-
gressive and irreversible degeneration of retinal ganglion
cells whose axonal projections constitute the optic nerve
[42–44]. It is currently the leading cause of irreversible
blindness worldwide [45] and by the year 2020 is projected
to aﬀect more than 76 million people [46]. Currently, the
standard clinical treatment for glaucoma is based solely on
lowering the intraocular pressure (IOP) of those aﬀected
through pharmacology, laser treatment, or surgery. However,
surgery and laser treatment carry risks and often require fur-
ther intervention or a combinational approach supplement-
ing with additive topical therapies throughout a patient’s
life [46]. The need for such regular treatment, often with
multiple diﬀerent eye drops administered several times per
day, means patient compliance is a challenge, and even in
those adhering to treatment, a signiﬁcant fraction continues
to experience progressive visual loss even after their IOP is
reduced [47, 48]. Therefore, there exists a great deal of
interest in new therapeutic approaches which can be oﬀered
as a single injection directly into the eye and that lead to
long-lasting or permanent beneﬁcial outcomes.
Much of adult glaucoma has an unclear, heterogeneous
etiology involving multiple genetic factors, individual risk
factors, and environmental factors [43, 46, 49]. For these rea-
sons, gene therapies for adult-onset glaucoma have focused
primarily on neuroprotection, which involves slowing the
loss of RGCs by altering their physiology to limit the patho-
genesis of the disease. This can be accomplished in two ways:
(1) by enhancing the activity of innate survival pathways in
RGC or (2) by inhibiting the progression of cell death.
2.1. Enhancing the Activity of Innate Survival Pathways.
Neurotrophic factors are known to promote neuron survival
through activation of prosurvival pathways or inhibition of
default apoptotic pathways when a cell experiences patho-
physiological stress [50–52]. During development of the
central nervous system, immature neurons require trophic
factors to survive, diﬀerentiate, and establish synaptic con-
nections. To control these developmental processes, some
neurotrophic factors are expressed in limited quantities by
target tissues and only neurons exposed to optimal neuro-
trophic levels survive and establish synaptic connections
[53]. Neurotrophic factors have also been studied as poten-
tial neuroprotective factors in neurodegenerative diseases,
with brain-derived neurotrophic factor (BDNF) and ciliary-
derived neurotrophic factor (CNTF) both having been shown
to protect axotomized RGC [54–56] and RGC in animal
models of glaucoma [16, 57–61].
The biological eﬀects of neurotrophins are mediated
by cell surface receptors. BDNF acts by binding to the
receptor tropomyosin-related kinase B (TrkB), which stim-
ulates multiple signalling pathways within RGC, including
extracellular signal-regulated kinases 1/2 (Erk 1/2) and
the phosphatidylinositol-3 kinase (PI3K)/Akt pathways
[12, 44, 62]. These pathways have been shown to play a
key role in promoting neuronal survival and regeneration.
Additionally, RGC are trophically dependent on BDNF with
BDNF strongly expressed in the superior colliculus [63, 64]
and transported retrogradely by RGC axons to ganglion cell
bodies in the retina during both development and into adult
life [65–69]. There is also substantial evidence that depletion
of BDNF plays a central role in the onset of glaucoma, with
evidence for impaired retrograde BDNF transport found in
experimental models of ocular dysfunction [58, 70, 71].
Research conducted over the past two decades has consis-
tently shown that intraocular injection of BDNF protein or
AAV-mediated BDNF expression provides a robust but
temporary neuroprotective eﬀect on RGC after optic nerve
transection or crush [54–56] or following ablation of the
superior colliculus [72]. While these results oﬀer promise
for the use of neuroprotective strategies in glaucoma, overex-
pression of BDNF can cause tachyphylaxis of the survival
response through downregulation of TrkB and its subsequent
degradation [73]. Studies by Cheng et al. [12] have also found
that mRNA levels of TrkB were reduced to 40% of their nor-
mal level following optic nerve transection in rats, and more
recently, Guo et al. [74] used RGC-enriched mRNA samples
from glaucomatous retinas and demonstrated a 97% decrease
in TrkB message indicating that supplementation alone may
not be suﬃcient in the long term.
Interestingly, combining AAV-CMV TrkB transduction
with an intraocular injection of exogenous BDNF in vivo
showed markedly increased neuronal survival compared to
expressing TrkB alone [12]. At 2 weeks after axotomy,
AAV TrkB with BDNF protected 76% of RGCs, whereas
independent administration of BDNF or AAV TrkB pro-
moted 38% or 27% neuronal survival, respectively [12]. This
would imply a gene therapy strategy to increase both ligand
and receptor expression which may provide a more potent,
long-term treatment.
CNTF, which is expressed in all retinal cell layers, has
also been identiﬁed as a potential neuroprotective agent for
glaucoma gene therapy. Intravitreal injection of CNTF and
adenoviral-mediated CNTF expression has been shown to
increase STAT3 in RGC, implicating the JAK–STAT path-
ways as the pathway responsible for its survival eﬀect [75].
In a study by Leaver et al. [57], intravitreal injection of
AAV-CAG CNTF signiﬁcantly increased RGC survival at
7 weeks after optic nerve crush and regenerating axons
were visible in the distal optic nerve. Another study by
Pease et al. [59] also found that AAV-CAG CNTF reduced
axonal loss by 15% compared to control groups following
laser-induced IOP elevation [55]. A potential limitation of
CNTF is that exogenous gene transfer of CNTF impairs
visual function in a dose-dependent manner [76], adversely
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aﬀecting photoreceptor function [77–79]. It has also been
shown to cause increased aberrant dendritic growth and
a signiﬁcant reduction in the complexity of the RGC den-
dritic arbor in both transduced and nontransduced RGC
populations [80, 81].
Neurotech Pharmaceuticals has recently commenced
a phase 2 clinical for its NT-501 encapsulated cell ther-
apy, based on the therapeutic beneﬁts of CNTF (http://
clinicaltrials.gov/ct2/show/NCT02862938). This experimen-
tal treatment for glaucoma consists of surgically implanting
small capsules into the eye, which are ﬁlled with human cells
modiﬁed to secrete a steady stream of CNTF. Subjects will be
followed for two years following implantation and will give
greater insight into the therapeutic potential of sustained
CNTF signalling.
2.2. Strategies to Inhibit Cell Death Pathways. Other
approaches to gene therapy for glaucoma have explored the
therapeutic potential of antiapoptotic proteins that inhibit
the progression of RGC apoptosis. RGC have been shown
to die by apoptosis in both experimental [82] and human
glaucoma [83]. Caspase activity is the ﬁnal common element
central to the implementation of apoptosis in RGC, making
caspase inhibitors an appealing prospect for neuroprotective
glaucoma therapies. Taking this approach, McKinnon et al.
[84] injected an AAV-CAG vector expressing a known cas-
pase inhibitor, baculoviral IAP repeat-containing protein-4
(BIRC4), into one eye on rat models of glaucoma. BIRC4
was shown to signiﬁcantly promote RGC survival, although
signiﬁcant diﬀerences in IOP exposure among treatment
groups were observed. However, it should be noted that
apoptosis plays an important role in controlling cell popula-
tions throughout the body and inhibitors of apoptosis have
had limited success as therapies to date.
Aﬀected by many proapoptotic stimuli, mitochondria
also play a key role in determining the cell’s fate, making
them important therapeutic targets [85]. Proteins of the
Bcl-2 family have been of particular interest as important
mediators of mitochondrial integrity. In particular, Bcl-XL
has been shown to repress apoptosis through the sequestra-
tion of proapoptotic proteins [86]. Malik et al. [85] showed
that AAV2-SYN1-mediated overexpression of Bcl-XL in
RGC of adult rat retinas provided a signiﬁcant neuroprotec-
tive aﬀect to optic nerve transections. 94% of transduced
RGC survived the lesion compared to 15% of control
RGC, and after 8 weeks, 46% of Bcl-XL overexpressing
RGC remained viable. Modest improvements have also
been observed with AAV2 neuron-speciﬁc enolase overex-
pression of Bcl-2-associated athanogene-1 (BAG1), an
Hsp70/Hsc70-binding protein, which has been shown to
suppress apoptosis and enhance neuronal diﬀerentiation
through interaction with the MAPK cascade [87].
It has also been suggested that RGC experience greater
metabolic stress than other retinal neurons. A study by
Williams et al. [88] hypothesized that RGC go through a
period of mitochondrial stress and metabolite depletion,
which causes them to undergo greater fatty acid metabolism.
Fatty acid beta-oxidation in particular can increase free-
radical generation leading to a greater consumption of
NAD+ [89], reducing its levels and leaving RGC vulnerable
to damage from elevated IOP. To test this theory, an NAD+
precursor nicotinamide (vitamin B3) was orally administered
at a high dose (2000mg/kg per day) to DBA/2J mouse
models of chronic, age-related, inherited glaucoma. At this
high dose, 93% of eyes tested did not develop glaucoma over
the 12-month study. As a single-dose therapy, AAV2-CMV
expressing Nmnat1, a terminal enzyme involved in the last
step of NAD+ production, was administered to DBA/2J mice.
This protein was expressed in 83% of RGC at 2 weeks, and its
overexpression was thought to drive further NAD+ produc-
tion, thus preventing axon and soma loss, preserving axon
transport and electrical activity in RGC and preventing
glaucomatous nerve damage in more than 70% of treated
eyes [88]. While further studies are needed to validate these
ﬁndings in other models, combining this single molecule
supplement with current glaucoma treatment may have a
substantial impact on preventing progressive RGC death in
glaucoma and could demonstrate therapeutic potential in
other age-related diseases.
While neuroprotective approaches have shown promise,
further developments will need to be made before these
gene therapies can reach clinical use. Due to the slow pro-
gression of glaucoma, prolonged gene expression may be
necessary to produce signiﬁcant clinical beneﬁt. However,
prolonged expressions of BDNF and CNTF have been
shown to alter the dendritic structure of both transduced
and nontransduced RGC populations [81], although the
functional importance of these changes remains uncertain.
Additionally, long-term AAV-mediated secretion of BDNF
or CNTF has been shown to signiﬁcantly change the expres-
sion of endogenous retinal genes in transduced and non-
transduced retinal tissue [90]. An analysis of unﬁxed whole
retinal tissue infected with either AAV2-BDNF-GFP or
AAV2-CNTF-GFP showed that 56% of the 93 retinal genes
tested had signiﬁcantly altered expression compared to
control AAV2-GFP retinas with greatest fold changes in the
RGC layer. Three times as many genes were altered after
receiving CNTF treatment in comparison to BDNF treat-
ment [90]. Long-term studies will need to be carried out
to account for potentially adverse eﬀects resulting from
extended manipulation of gene expression and alterations
in endogenous gene expression.
3. Gene Therapy to Treat Early-Onset Glaucoma
Unlike most forms of adult-onset glaucoma, early-onset
glaucoma more frequently has a single genetic cause.
Myocilin- (MYOC-) dominant gain-of-function mutations
have been reported in approximately 4% of all primary open-
angle glaucoma (POAG) cases, but 10–33% of juvenile open-
angle glaucoma cases harbour a MYOC mutation [91, 92].
While they do not directly disrupt RGC function, these
mutations have been shown to aﬀect trabecular meshwork
(TM) functioning and lead to elevated IOP [93]. Mutations
in the genes encoding cytochrome P450 have also been
identiﬁed in 40% of individuals with primary congenital
glaucoma [92, 94]. With advances in the speciﬁcity and eﬃ-
ciency of genome editing tools, there exists the possibility
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that these mutations can be targeted therapeutically. In a
recent study by Jain et al. [91], adenoviruses expressing
CRISPR/Cas9 components (Ad5-cas9 and Ad5-crMYOC)
were used to target dominant MYOC mutations in a mouse
model of myocilin-associated POAG. Cas9 was shown to
eﬀectively disrupt the mutant MYOC gene, lowering IOP in
treated mouse eyes and preventing further glaucomatous
damage to RGC. In the same study, these constructs were
used to treat trabecular meshwork tissue in human ex vivo
cultured eyes [91]. A reduction of myocilin mRNA was
observed, suggesting the feasibility of translating this tech-
nology to patients with MYOC mutations.
4. Gene Therapy to Treat Leber’s Hereditary
Optic Neuropathy
Leber’s hereditary optic neuropathy (LHON) is an optic
nerve disorder characterized by rapid, painless visual loss in
one eye, shortly followed by successive visual loss in the
remaining eye [95]. The disease is seen more predominantly
in men, and symptoms appear in the second to third decades
of life [65]. LHON is caused by point mutations in mitochon-
drial DNA (mtDNA). Three of the most common mutations,
causing approximately 95% of LHON cases, lead to decreased
NADH dehydrogenase activity in complex I of the mitochon-
drial respiratory chain and a reduction in energy production
by the mitochondria [96–98]. In particular, mutation of
the NADH dehydrogenase subunit 4 complex I (ND4) gene
(G11778A) is present in 60% of LHON cases worldwide
[99]. Though these genes are expressed in all mitochondria,
the disease phenotype is limited to loss of RGC and degener-
ation of the optic nerve [100], possibly due to increased RGC
energy demands. The majority of individuals with LHON are
homoplasmic, meaning they carry only mutant mtDNA.
Approximately 15% of LHON patients are heteroplasmic
for the primary LHON mutation, with varying proportions
of mutated and wild-type mtDNA present in peripheral
blood leukocytes [101].
There is currently no deﬁnitive treatment for LHON.
While current interventions of idebenone and vitamin B12
therapy have been eﬀective in some patients, they have no
eﬀect in others [102]. Within the last decade, gene therapy
research for LHON has advanced signiﬁcantly, from the ﬁrst
LHON animal model by Qi et al. [103] to recent clinical trials
supporting the feasibility of using gene therapy to treat this
disorder through allotropic expression of the corrected mito-
chondrial gene sequences. The future treatment for LHON is
likely to be through (1) incorporating new mitochondrial
DNA via AAV or (2) CRISPR/Cas9 technology for mtDNA
editing which may provide potentially novel avenues to treat
heteroplasmic LHON mutation.
4.1. Incorporating Mitochondrial DNA via AAV.How LHON
disease pathology develops is determined by the balance
between the amounts of mutant and normal protein (typi-
cally ND4) expressed in RGC [100]. As a result, gene therapy
studies have focused on promoting expression of the normal
protein in a degree high enough to prevent RGC degenera-
tion. Currently, viral vectors can only transfer genes to the
nucleolus and not directly to mammalian mitochondria. To
overcome this limitation, Guy et al. [104] developed what
has become the foundation for allotropic expression of
LHON mitochondrial genes. AAV-CAG were used to
construct a nuclear version of the mitochondrial gene which
codes for cytoplasmically expressed proteins. The proteins
generated contain a mitochondrial targeting sequence, which
allows for eﬀective traﬃcking to their target site in the mito-
chondria [104]. This method was validated in vivo using a rat
model of LHON, where electroporation of a construct carry-
ing the wild-type ND4 allele eﬀectively protected against
RGC degeneration using allotropic expression [105].
Validating this method has led to rapid advances in
LHON gene therapy. In 2015, Cwerman-Thibault et al.
[106] introduced a recombinant AAV2 containing ND4 into
a rat model of LHON, demonstrating both the safety and
eﬃcacy of allotropic ND4 expression in treating LHON. This
approach suppressed RGC degeneration and preserved visual
function in mutant ND4 rodents, making it an appealing
candidate for human LHON clinical trials.
Recently, the results of the ﬁrst three clinical trials of
LHON gene therapy were released and provide promising
prospects for the future. A study by Wan et al. [96] carried
out at Tongji Hospital in Wuhan, China, evaluated the safety
and eﬃcacy of AAV2-mediated allotropic expression of ND4
in nine patients with the G11778A mutation. AAV-ND4 was
injected in one eye each in each of nine patients, all of whom
had been diagnosed for over a year. Each patient was
followed for nine months. Over that period, none of the
patients showed local or systemic adverse side eﬀects from
the treatment and visual acuity of 6 of the 9 patients showed
signiﬁcant improvement. In particular, patient 1 improved
from 2 to 1.1 log MAR and was able to read newspaper head-
lines after treatment and patient 6 (a 9-year-old female)
improved her visual acuity from 1.2 to 0.4 log MAR, allowing
her to return to school and study with her classmates [96].
The results of phase I clinical trials performed in the
United States by Guy et al. [107] also showed modest but sta-
tistically signiﬁcant improvements of visual acuity following
allotropic LHON gene therapy. 14 patients in three groups
with varying durations of vision loss were recruited for this
study, which administered low andmedium doses of the gene
therapy. Similar to the Chinese study, no serious safety
concerns were associated with allotropic gene therapy of
LHON [96, 107]. Following intravitreal injection, improve-
ments in treated eyes were observed within 7 to 30 days
[107], a duration when expression was observed in 90%
of rodent RGC as reported by Koilkonda et al. [108].
High-dose cohorts are now being established for the next
phase of clinical testing.
Similar to the previous studies, Vignal et al. [109] con-
ducted a single-centre phase 1/2 clinical trial of rAAV2/2-
ND4 that included 15 subjects and 4 dose-escalation
cohorts (9× 109 vector genomes [vg]/eye, 3× 1010 vg/eye,
9× 1010 vg/eye, and 1.8× 1011 vg/eye). The study found that
rAAV2/2-ND4 was safe and well tolerated 2 years after a sin-
gle intravitreal administration with an observed between-eye
diﬀerence in visual acuity change from baseline noted at
week 96, favouring the treated eye.
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While still in its early stages, the ﬁndings of these studies
support the development of further clinical studies on allo-
tropic gene therapies for LHON, but with larger patient
cohorts. With mild improvements reported, it is reasonable
to assume that normal ND4 was eﬀectively targeted to the
mitochondria and was able to increase energy supply to the
optic nerve in both studies [96, 107]. Initial ﬁndings suggest
that the degree of response to treatment is highest when
treatment is administered at 1 year of visual loss [107]. In
future studies, the duration of visual loss and degree of
remaining optic nerve function will be important consider-
ations to determine the timing of administration and clinical
eﬃcacy of each LHON gene therapy.
4.2. CRISPR/Cas9 Gene Shifting. Gene shifting describes
the process of selectively destroying mutant mtDNA while
preserving normal mtDNA in heteroplasmic mitochondrial
diseases, which make up approximately 15% of LHON
cases [110]. As described previously, the development of
LHON is the result of the balance between the amount of
normal and mutant protein [100]. The majority of mtDNA
mutations cause disease when the level of heteroplasmy
exceeds 70–80% [111].
Advances in the CRISPR/Cas9 system for eﬃcient
genome editing in mammals have opened up new avenues
for intervention of inherited diseases. Studies by Hung et al.
[39] have demonstrated that CRISPR/Cas9 components can
eﬃciently target RGCs and achieve high levels of gene knock-
out in vivo using a dual AAV2 system. While CRISPR/Cas9
has been widely used to edit nuclear DNA, it has been unclear
whether this system could be applied to edit mtDNA, with
the mitochondrial inner membrane presenting a substantial
entry barrier to AAVs. In a recent study, Jo et al. [112]
demonstrated that FLAG-Cas9 is able to localize to the
mitochondria with sgRNAs to edit mitochondrial DNA in a
site-speciﬁc manner. To overcome nonspeciﬁc distribution
of FLAG-Cas9, a mitochondria-targeted Cas9 (mitoCas9)
was also created which localizes only to the mitochondria
to produce site-speciﬁc cleavage of mtDNA. While further
validation of this approach and analysis of oﬀ-target editing
would be necessary, advances in CRISPR/Cas9 technology
for mtDNA editing presents an opportunity to study the
eﬀects of gene shifting through knockout of mtDNA. With
continued advances in this technology, future studies on
AAV-mediated genome editing in heteroplasmic LHON
cases may be possible.
Taking a diﬀerent approach, the concept of gene shifting
could potentially be applied to reduce mutant mtDNA copies
in the oocytes of women carrying LHON mutations. In a
recent study by Reddy et al. [113], mitochondrial targeted
endonucleases known as mitoTALENs were able to eliminate
mutant mitochondrial haplotypes in both mice oocytes and
one-cell embryos, leaving only the selected mtDNA haplo-
type. This heteroplasmy shift resulted in phenotypically nor-
mal animals and prevented transmission of the eliminated
mtDNA haplotypes to future oﬀspring [113]. Additionally,
mitoTALENs targeting the 14459G>A human LHON muta-
tion were able to successfully reduce mutant mtDNA in
mouse oocytes 24 hours after infection [113].
While there is a long way to go in further developing
these technologies, genome-editing techniques are advancing
at an astonishing rate. The development of CRISPR/Cas9 in
particular demonstrates several advantages in comparison
to ZFNs or TALENs. CRISPR/Cas9 has been shown to be
more eﬃcient at inducing genetic modiﬁcations [114] and
can be easily adapted to target diﬀerent DNA sites requiring
only a simple modiﬁcation to the 20 bp protospacer region of
the gRNA, whereas ZFNs and TALENs require recoding of
proteins using large 500–1500 bp DNA segments [115].
Cas9 also has the unique advantage of being able to induce
double-stranded breaks at numerous sites in parallel using
multiple RNA guides [37]. Ensuring the elimination of oﬀ-
target cleavage with these editing techniques remains a
primary concern [35] and justiﬁable barrier to clinical use.
Additional consideration is also needed regarding when or
if these types of intervention are necessary. Only 50% of male
and 10% of female patients with the G11778A LHON muta-
tion actually develop visual loss [99]. While predictions of
susceptibility to disease can be made, making unnecessary
modiﬁcations could pose a signiﬁcant risk to what might be
otherwise healthy eyes.
5. Conclusion
Substantial developments in technology over the past two
decades have made glaucoma and LHON exciting potential
targets for gene therapy. While further trials with larger
patient cohorts are needed, initial results of LHON gene
therapy clinical trials demonstrate the progress made and
prospects for future clinical use of gene therapy. Future
research will need to determine the ideal timing of gene
therapy administration and whether a “critical window”
for eﬀective treatment exists either before or after symp-
toms occur. While many hurdles will need to be overcome
before glaucoma gene therapy treatments reach routine
clinical use, our advances in understanding the disease’s
pathology and our achievements in RGC neuroprotection
in animal models provide grounds for optimism. Moving
forward, the most challenging aspect of translating these
ﬁndings will be determining the best avenue for RGC neu-
roprotection. Several diﬀerent animal models of glaucoma
and optic nerve disease are currently used in research, with
each having advantages and limitations. Clinically, the pre-
sentation of glaucoma pathology also varies signiﬁcantly.
Determining the most eﬀective pathway to target will
depend heavily on the speciﬁc features of each case. In
some patients, multiple pathways may contribute to the
onset of the disease. Nevertheless, these rapid developments
and successes achieved thus far give reason to believe that
novel clinical therapies are on the horizon.
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